IPM514
/ Immupeutics Medicine
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
October 03, 2025
A Study of IPM514 in Patients With Esophageal Squamous Cell Carcinoma.
(clinicaltrials.gov)
- P1 | N=36 | Not yet recruiting | Sponsor: Beijing Immupeutics Medicine Technology Limited
New P1 trial • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Oncology • Squamous Cell Carcinoma
1 to 1
Of
1
Go to page
1